Inloggen

Login
 
Wachtwoord vergeten?

Analisten over UniQure

Volgen
 
Klik hier om dit forumtopic te volgen en automatisch op de hoogte gehouden te worden bij nieuwe berichten.
236 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 | Laatste
Aantal posts per pagina:  20 50 100 | Omlaag ↓
[verwijderd]
0
quote:

pim f schreef op 18 apr 2019 om 09:21:


highlightpress.com/2019/04/17/uniqure...

1x Sell, 1x Hold en 12x Buy en de kop is "Sell". Highlight Press heeft voor mij afgedaan !
Tex Mex
1
Toe maar: Chardan analyst Gbola Amusa raised his price target for uniQure (QURE) to $175 from $100 to reflect the company's opportunity in Huntington's disease.

twitter.com/zbiotech/status/112903186...
pim f
0
quote:

Tex Mex schreef op 16 mei 2019 om 16:58:


Chardan analyst Gbola Amusa raised his price target for uniQure (QURE) to $175 from $100 to reflect the company's opportunity in Huntington's disease.


Hoppa, niet van dat benauwde gepriegel
pim f
0
quote:

Tex Mex schreef op 16 mei 2019 om 16:58:


Toe maar: Chardan analyst Gbola Amusa raised his price target for uniQure (QURE) to $175 from $100 to reflect the company's opportunity in Huntington's disease.

twitter.com/zbiotech/status/112903186...


Chardan Capital Reiterates a Buy Rating on uniQure NV (QURE)
May 16, 2019

Amusa noted: "We believe uniQure, a 2019, could be en route to $5-10bn valuation, based on support in the coming year from what could be a best-in-class, breakthrough Huntington's disease (HD) franchise. HD is a universally fatal monogenic (autosomal dominant) disease that usually starts between ages 30 and 50, followed by movement, cognitive, and psychiatric impairment. Death typically follows 10 to 30 years after diagnosis. In 2H19, uniQure is expected to make AAV5-based gene therapy (GT), AMT-130, the first 1-time GT to enter the clinic for HD. AMT-130 utilizes uniQure's miQURE silencing technology to inhibit the production of the mutant huntingtin protein (mHTT).

www.markets.co/chardan-capital-reiter...
Prof. Dollar
0
Prof. Dollar
0
quote:

Prof. Dollar schreef op 17 mei 2019 om 14:28:


Video van corporate update uniQure gegeven eind april door Jon Garen, Chief Business Officer. TNX flosz
www.youtube.com/watch?v=WMt2Afh_Wgc

Ah, had ik eigenlijk in ander draadje willen plaatsen... het zij zo.
pim f
0
Brokerages Set Uniqure NV (QURE) Price Target at $75.89

Posted by Brian Wu on May 18th, 2019

Uniqure logoUniqure NV (NASDAQ:QURE) has been assigned an average rating of “Buy” from the fourteen research firms that are covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $77.22.

Several research analysts have weighed in on QURE shares. Zacks Investment Research upgraded Uniqure from a “sell” rating to a “hold” rating in a research report on Thursday, January 17th. SunTrust Banks increased their price objective on Uniqure to $76.00 and gave the stock a “buy” rating in a research report on Tuesday. BidaskClub upgraded Uniqure from a “sell” rating to a “hold” rating in a research report on Tuesday. Robert W. Baird started coverage on Uniqure in a research report on Thursday, March 28th. They set an “outperform” rating and a $85.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating on shares of Uniqure in a research report on Tuesday, February 26th.

mayfieldrecorder.com/2019/05/18/broke...
colt
0
30 mei 2019, Volgens InvestorPlace Media:

Als het op biotech-aandelen betref, is uniQure (NASDAQ: QURE ) royalty-royalty's.
Izette
0
quote:

colt schreef op 31 mei 2019 om 15:14:


30 mei 2019, Volgens InvestorPlace Media:

Als het op biotech-aandelen betref, is uniQure (NASDAQ: QURE ) royalty-royalty's.


uniQure NV (QURE)

When it comes to biotech stocks, uniQure (NASDAQ:QURE) is gene therapy royalty. That’s because the firm actually created and launched the very first successful gene therapy back in 2012. However, due to the cost of the drug, it was never prescribed. But QURE has turned that successful approval into a platform for further successful development.

This includes the biotech stock’s latest work for hemophilia. QURE has seen great success with its gene therapy program for the blood disorder. After seeing amazing initial results, QURE has moved its top hemophilia medication — AMT-061 — into phase I/IIb trials. This news sent the clinical stage biotech stock up more than 34%. Given its past history of navigating the gene therapy waters to approval, QURE could have another hit on its hand.

Elsewhere, the firm has started trials for the first gene therapy targeting Huntington’s disease and has gene therapies for congestive heart failure in pipelines. All of these are much more “popular” issues and should help QURE actually see prescription growth if successful.

Like most clinical-stage biotech stocks, QURE is a gamble. But it’s a more calculated risk than most given its history and how great its previous results were.
Izette
0
Dit zegt technisch analist Zacks Investment Research over de stijging van gisteren;

uniQure N.V. QURE was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $57.28 to $63.49 in the past one-month time frame.

The company has seen one negative estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

uniQure currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
236 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Markt vandaag

Wall Street op winst na cijferregen

19:41 De aandelenbeurzen in New York stonden dinsdag op winst. Beleggers op Wall Street verwerkten een fikse hoev...

    Indices

    AEX 582,08 +1,84%
    EUR/USD 1,1147 -0,66%
    Germany30^ 12.552,60 +2,14%
    Gold spot 1.417,35 -0,56%
    LDN100-24h 7.530,79 +1,27%
    NY-Nasdaq Composite 8.204,14 -0,04%
    US30# 27.337,93 +0,60%

    Stijgers

    BESI
    +9,03%
    Aperam
    +8,66%
    Arcadis
    +8,62%
    TomTom
    +8,32%
    Arcelo...
    +8,09%

    Dalers

    Kiadis...
    -6,18%
    Basic-Fit
    -4,14%
    ABN AM...
    -2,84%
    ASR Ne...
    -2,68%
    KPN
    -2,35%